Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vor Biopharma Inc. filings document a clinical-stage biotechnology issuer focused on telitacicept and autoimmune disease development. The record includes Form 8-K disclosures for operating and financial results, Regulation FD presentations, clinical and regulatory updates, material agreements, governance changes and capital-structure matters.
Proxy materials describe director elections, equity incentive plan matters, auditor ratification and annual-meeting voting procedures. Other filings address executive compensation arrangements, Nasdaq-listed common stock, a reverse stock split, equity plan share adjustments and security-holder rights tied to the company’s common stock and outstanding awards.
Vor Biopharma Inc. (NASDAQ: VOR) received Amendment No. 5 to a Schedule 13D from RA Capital Management, L.P. and related parties, updating their beneficial ownership information as of 25 June 2025.
The filing shows that the reporting group – RA Capital Management, its principals Peter Kolchinsky and Rajeev Shah, and affiliated funds – currently holds a combined 39,739,850 shares of Vor common stock, representing 31.8 % of the company’s outstanding shares. All voting and dispositive power over these shares is reported as “shared.” No shares are held with sole voting or dispositive power.
Breakdown of the reported position:
- 37,820,713 shares held directly by RA Capital Healthcare Fund, L.P.
- 1,825,326 shares held by RA Capital Nexus Fund, L.P.
- 21,121,449 shares underlying common-stock warrants held by the Fund (subject to a 9.99 % beneficial-ownership blocker).
- 200,000,000 shares underlying pre-funded warrants held by the Fund. These warrants are not currently exercisable because Vor lacks sufficient authorized but unissued shares.
- 93,811 shares underlying vested stock options held by Joshua Resnick for the benefit of RA Capital.
The warrants include “beneficial-ownership blockers” that prevent exercise if the reporting group’s ownership would exceed 9.99 % of Vor’s outstanding common stock. Consequently, the large warrant positions are not reflected in the 31.8 % ownership calculation.
RA Capital states that its operating entities have delegated sole voting and investment power to RA Capital Management. The individual principals disclaim beneficial ownership except for Section 13(d) reporting purposes.
Jean-Paul Kress, CEO, Chairman and Director of Vor Biopharma, was granted a significant stock option award on June 26, 2025. The derivative securities transaction involved 83,296,638 stock options with the following key terms:
- Exercise price set at $0.89 per share
- Options expire on June 25, 2035
- Vesting schedule: 25% vests on June 26, 2026, with remaining 75% vesting in equal monthly installments over 3 years
- Vesting contingent on continued service with company
This substantial equity grant aligns the CEO's interests with shareholders and suggests long-term commitment to the company. The low exercise price relative to typical biotech stock prices may indicate recent market challenges or strategic compensation planning.
Jean-Paul Kress has filed a Form 3 (Initial Statement of Beneficial Ownership) with the SEC upon joining Vor Biopharma (NYSE: VOR) as CEO and Chairman of the Board, effective June 25, 2025.
Key details from the filing:
- Kress currently holds no beneficial ownership of any Vor Biopharma securities, either direct or indirect
- He serves in dual roles as both Director and Executive Officer
- The filing was submitted by attorney-in-fact Sherell Bacchas on June 27, 2025
- Business address is listed as 100 Cambridgepark Drive, Suite 101, Cambridge, MA
This Form 3 filing is a standard regulatory requirement for new officers and directors of public companies, establishing their initial securities ownership baseline for future transaction reporting.